Intranasal Administration

2

Review clinical trials related to Intranasal Administration. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression

Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.

Participants needed: 164
Trial details
Phase: Phase 4Age: 18+Biological sex: FemaleType: InterventionalSponsor: Peking University First HospitalUpdated: Jun 15, 2026Locations: 1
Eligibility criteria

Pregnant women aged ≥18 years who are preparing for childbirth; [+1]

History of schizophrenia or existence of communication barriers; [+5]

Status: Recruiting

Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients

Postoperative pain after adenoid and tonsil surgery is significant, with approximately 75% of pediatric patients experiencing severe postoperative pain. Currently, there is a lack of clinical strategies to safely and effectively manage postoperative pain in children undergoing adenoid and tonsil surgery. Dexmedetomidine and esketamine can achieve appropriate sedation levels and alleviate postoperative pain when used in children. Both drugs can be administered intranasally, and their pharmacological effects complement each other, reducing side effects. This study aims to investigate whether intranasal administration of dexmedetomidine-esketamine combination can improve postoperative analgesia in children undergoing adenoid and tonsil surgery.

Participants needed: 160
Trial details
Phase: Phase 4Age: 3-7Biological sex: AllType: InterventionalSponsor: Peking University First HospitalUpdated: Apr 9, 2026Locations: 1
Eligibility criteria

Aged 3-7 years old. [+2]

Unsuitable for intranasal administration due to nasal diseases (such as rhinitis... [+8]